The latter is highly relevant for TKIs as polypharmacy is common in cancer patients: for example, in acute myeloid leukemia (AML) treatment clinically relevant pharmacokinetic interactions have been described between the FLT3 inhibitors (midostaurin and gilteritinib) and azole antifungals (9, 10). The gene discussed is FLT3; the disease is acute myeloid leukemia.